{
  "ticker": "SOM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973693",
  "id": "02973693",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0911",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7rj6l7h7rk4.pdf",
  "summary": "**FY25 Q4 Quarterly Report (Appendix 4C) \u2013 Key Highlights:**  \n- **Revenue**: Q4 FY25 **$30.1m** (+25.1% YoY, +17.9% constant currency). Full-year revenue **$111.5m** (exceeds guidance >$105m).  \n- **Profitability**: FY25 EBITDA expected **top end of $7m\u2013$9m range** (excludes $3.0m lease payments, restructuring costs).  \n- **Cash Flow**: Positive free cash flow of **$0.8m**; closing cash balance **$17.3m** (net cash **$16.5m**).  \n- **Capacity Expansion**: 25% production boost expected in FY26; backlog cleared.  \n- **Rest Assure\u00ae**: Clinical study validates efficacy; FDA trial prep underway for 510k submission.  \n\n*(Omitted: CEO quotes, regional breakdowns, non-material operational updates.)*",
  "usage": {
    "prompt_tokens": 1740,
    "completion_tokens": 206,
    "total_tokens": 1946,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:26:28.220614"
}